about
Effect of rifaximin on gut microbiota composition in advanced liver disease and its complicationsWhat we should know about portal vein thrombosis in cirrhotic patients: a changing perspectiveBridging and downstaging treatments for hepatocellular carcinoma in patients on the waiting list for liver transplantationDiagnosis of bowel diseases: the role of imaging and ultrasonography.Physiology and pathophysiology of liver lipid metabolism.Diagnosis and treatment of small intestinal bacterial overgrowth.The Role of Antibiotics in Gut Microbiota Modulation: The Eubiotic Effects of Rifaximin.Rifaximin for the treatment of irritable bowel syndrome - a drug safety evaluation.Management of hepatitis C virus infection recurrence after liver transplantation: an overview.Use and indications of cholestyramine and bile acid sequestrants.The metabolic and toxicological considerations for mTOR inhibitors in the treatment of hepatocarcinoma.Portal vein thrombosis and liver transplantation: implications for waiting list period, surgical approach, early and late follow-up.Recipient female gender is a risk factor for graft loss after liver transplantation for chronic hepatitis C: Evidence from the prospective Liver Match cohort.Long-term maintenance of sustained virological response in liver transplant recipients treated for recurrent hepatitis C.Prevention and treatment of hepatic encephalopathy: focusing on gut microbiota.Treatment of hepatitis C recurrence is less successful in female than in male liver transplant recipients.Early prediction of response to sorafenib in patients with advanced hepatocellular carcinoma: the role of dynamic contrast enhanced ultrasound.Thrombotic risk factors in patients with liver cirrhosis: correlation with MELD scoring system and portal vein thrombosis development.Portal vein thrombosis occurrence in a cirrhotic patient during treatment with rivaroxaban.Treatment of genotype-1 hepatitis C recurrence after liver transplant improves survival in both sustained responders and relapsers.Hepatocellular Carcinoma is Associated with Gut Microbiota Profile and Inflammation in Non-Alcoholic Fatty Liver Disease.Treatment of early stage chronic hepatitis C virus infection.Inducing tolerability of adverse events increases sorafenib exposure and optimizes patient's outcome in advanced hepatocellular carcinomaMorphological and functional consequences of transradial coronary angiography on the radial artery: implications for its use as a bypass conduit†Bacterial translocation in patients with liver cirrhosis: physiology, clinical consequences, and practical implicationsLetter: improvement of clinical outcomes by metformin in metabolic liver disease-a microbiota-dependent mechanism?Gut Microbial, Inflammatory and Metabolic Signatures in Older People with Physical Frailty and Sarcopenia: Results from the BIOSPHERE StudyGut microbiota compositional and functional fingerprint in patients with alcohol use disorder and alcohol-associated liver diseaseDiagnostic and therapeutic potential of the gut microbiota in patients with early hepatocellular carcinoma
P50
Q26775927-21CC2039-045B-488B-8765-AB6A1907AE0BQ26827793-CC5302EE-465A-495C-B9E1-0F1D0BEA55B9Q26852105-B61B7D4F-A168-4C4B-85AF-0BC3C72906AFQ30455406-44851B1C-5B2F-48DB-BC8D-5572E7C56D3BQ35662655-0490C66D-A82F-4D66-B171-B4524DF6B6ADQ35860893-F5B4BBDF-11FB-4B36-97FC-2D90EF567359Q35973636-D1FD1F4E-F448-48BF-9B74-727A1DF45C8BQ36009729-B5982061-1D65-45E2-B128-235DB0A128E7Q37844982-4A386974-DF43-4C08-AEE2-53AEA8C664DDQ37899074-991FAD39-15A1-4C38-8C6A-F4147D9A3139Q37950012-674AD90C-22B8-4BA5-89B0-C4A527348A96Q38192256-D5241A01-D7A8-4E1F-9132-29BD8AF4D7FBQ41175307-21E22471-9C8B-468B-99D6-42EB2AECE110Q42230987-ABC55070-7BDF-4C5D-99EF-B8BA079DBD05Q42407730-E2B4F29A-79FD-414A-BCAE-067951E892E9Q42977889-C3EEEFF0-B646-48BC-B6F8-48D10495D9A9Q45719507-4E3534DD-5E80-4FDB-899F-00AA89F7F13CQ47738072-5F858EA3-4B89-4945-9DF0-A2EE961CCB7DQ48154202-7FA36425-F4CF-4110-9F99-2AF0A4537F06Q50550145-D4E58364-5440-43DB-AA46-5B3563B93D91Q53408592-A4F874C8-777A-466B-8EA7-9B993C13309AQ53705211-D5551DE3-3760-40A7-B948-28AF777E7367Q61045894-DF1321BD-8D0B-4F17-9CC2-0D0C513BF68AQ62792207-CA22C176-6664-4100-8A0C-9F6F397296BEQ88880467-B01AEEA3-E6ED-4273-8C7F-D7AEE5E2B001Q92270735-81689C87-B6EA-4BE7-939B-D8FFCC935948Q92326187-2D46940A-78CA-4C44-9CC1-5CF09CF07827Q92725480-15CC3AFE-C87C-465C-B382-94100437F0C9Q92795035-B1554449-03A6-49AA-846B-A7F0DA771F4E
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Francesca Romana Ponziani
@an
Francesca Romana Ponziani
@ast
Francesca Romana Ponziani
@br
Francesca Romana Ponziani
@ca
Francesca Romana Ponziani
@co
Francesca Romana Ponziani
@da
Francesca Romana Ponziani
@de
Francesca Romana Ponziani
@en
Francesca Romana Ponziani
@es
Francesca Romana Ponziani
@eu
type
label
Francesca Romana Ponziani
@an
Francesca Romana Ponziani
@ast
Francesca Romana Ponziani
@br
Francesca Romana Ponziani
@ca
Francesca Romana Ponziani
@co
Francesca Romana Ponziani
@da
Francesca Romana Ponziani
@de
Francesca Romana Ponziani
@en
Francesca Romana Ponziani
@es
Francesca Romana Ponziani
@eu
prefLabel
Francesca Romana Ponziani
@an
Francesca Romana Ponziani
@ast
Francesca Romana Ponziani
@br
Francesca Romana Ponziani
@ca
Francesca Romana Ponziani
@co
Francesca Romana Ponziani
@da
Francesca Romana Ponziani
@de
Francesca Romana Ponziani
@en
Francesca Romana Ponziani
@es
Francesca Romana Ponziani
@eu
P1053
E-4136-2016
P106
P1153
35316450500
P21
P31
P3829
P496
0000-0002-5924-6238